Visa Direct Taps Stablecoins to Unlock Faster Funding for Businesses
30.9.2025 09:00:00 CEST | Business Wire | Press Release
The way businesses fund cross-border payments is about to get faster, smarter and more flexible. At SIBOS 2025, Visa announced it will launch a stablecoin prefunding pilot through Visa Direct, giving businesses a new way to move money globally – unlocking liquidity and modernizing treasury operations for the digital-first economy.
For decades, moving money across borders has depended on slow, costly systems that tie up capital in advance. With this pilot, Visa Direct is testing stablecoins as a new funding source. The goal: reduce friction, unlock faster access to liquidity and give financial institutions more flexibility in how they manage global payouts.
“Cross-border payments have been stuck in outdated systems for far too long,” said Chris Newkirk, President, Commercial & Money Movement Solutions, Visa. “Visa Direct’s new stablecoins integration lays the groundwork for money to move instantly across the world, giving businesses more choice in how they pay.”
Why it matters
- Liquidity unlocked: Stablecoin prefunding frees businesses from parking large fiat balances in advance, keeping capital working while still ensuring payouts are covered.
- Modernized treasury: Institutions can move money in minutes instead of days, making liquidity management more dynamic and responsive.
- Predictability: Stablecoins provide a consistent settlement layer, reducing exposure to local currency volatility and stabilizing treasury operations.
How the pilot works
- Stablecoin pre-funding:Businesses pre-fund Visa Direct with stablecoins instead of fiat to cover payouts. Visa treats those stablecoins as “money in the bank,” making funds available for payout.
- Who it’s for:Banks, remitters and financial institutions that need faster, more flexible ways to manage liquidity across borders.
- Availability: Visa is working with select partners that meet the pilot criteria. We plan to expand the pilot in 2026.
The Visa Direct stablecoin pilot builds on Visa’s broader commitment to building the future of money movement: one that is faster, more flexible and designed for the digital-first world. By combining the scale and trust of Visa’s global network with the programmability of blockchain and by partnering with leading payment providers on prefunding use cases, Visa is helping modernize cross-border payments for businesses, financial institutions and consumers worldwide.
FAQ
Q: What is Visa Direct?
Visa Direct is Visa’s real-time payments platform, enabling fast, secure payouts worldwide.
Q: What’s new about this pilot?
This is the first time Visa Direct is utilizing stablecoins. Instead of only using fiat, businesses can now prefund Visa Direct with stablecoins.
Q: Do recipients still get traditional money?
Yes. Recipients can always be paid in their local currency.
Q: Why now?
Cross-border rails were built decades ago and stablecoins can provide the necessary upgrade to make payments faster, cheaper and programmable.
Q: Who benefits?
Banks, remitters and businesses with high volume cross-border payouts that require faster, more efficient liquidity management.
Q: What’s next?
The initial pilot is expected to move into limited availability by April 2026.
About Visa
Visa (NYSE: V) is a world leader in digital payments, facilitating transactions between consumers, merchants, financial institutions and government entities across more than 200 countries and territories. Our mission is to connect the world through the most innovative, convenient, reliable and secure payments network, enabling individuals, businesses and economies to thrive. We believe that economies that include everyone everywhere, uplift everyone everywhere and see access as foundational to the future of money movement. Learn more at Visa.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930875370/en/
Contacts
Media Contacts
Jackie Dresch - jdresch@visa.com
Conor Febos – cfebos@visa.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom